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February 20, 2007:830–7 ACC/AHA Clinical Data Standardsreamble
he American College of Cardiology/American Heart As-
ociation (ACC/AHA) Task Force on Clinical Data Stan-
ards has undertaken the task to develop and publish
linical data standards—data elements and corresponding
efinitions that can be used in the measurement of patient
linical management and outcomes, and for research and
pidemiological assessments. A methodology has been cre-
ted that describes the formation of a diverse writing
ommittee, guidelines for selecting and defining the stan-
ards, and achieving consensus in the development of the
tandards, peer review, and publication including periodic
pdates. A systematic approach to defining data elements is
mportant for accurate and efficient performance of clinical
esearch, medical record documentation, and quality assess-
ent.
. Introduction
he ACC and AHA support the goals of their members to
mprove cardiovascular care and disease prevention through
rofessional education, promotion of research, development
f guidelines and standards for cardiovascular care, and
ostering policy that supports optimal patient outcomes.
In clinical care and in research studies, caregivers
ommunicate with each other through a common vocab-
lary. In the field of cardiology, large-scale clinical trials,
egistries, and other databases have provided a wealth of
nformation on hundreds of thousands of patients. These
ata have been used to define new therapies and improve
he quality of clinical care through evaluation of both care
rocess and outcomes for patients with a range of
ardiovascular conditions.
The integrity of clinical research depends in large part on
rm adherence to prespecified procedures for patient enroll-
ent and follow-up; these procedures are guaranteed
hrough careful attention to definitions enumerated in the
tudy design and case report forms. When data elements
nd definitions are standardized across studies, comparison,
ooled analysis, and meta-analysis are enabled, thus deep-
ning our understanding of individual clinical trials. This is
articularly important for meta-analyses of trials where
ifferences in data collection methods and in definitions
ay hamper the validity of these analyses.
I. Purpose and Scope of the
CC/AHA Clinical Data Standards
he ACC and the AHA recognize the importance of
tandardizing a common lexicon for describing the process
nd outcomes of clinical care, whether in randomized trials,
bservational studies, registries, or quality improvement
nitiatives. Broad professional agreement on a common bocabulary with common definitions will facilitate cross-
tudy comparisons. Also, when advantageous, the combin-
ng of data across studies will improve the assessment of any
roject’s generalizability to clinical practice.
The development of quality performance measurement
nitiatives, particularly those for which comparison of pro-
iders is an implicit or explicit aim, has further raised
wareness among the professional community regarding the
mportance of data standards. For the first time, a wide
udience, including non-medical professionals such as pay-
rs, regulators, and consumers, may draw conclusions about
are and outcomes. For understanding and comparison of
are patterns and outcomes to be fair, the data elements that
ompose the descriptions of these patterns and outcomes of
are must be clearly defined, consistently used, and properly
nterpreted by a broader audience than ever before.
To further efforts aimed at standardizing such a lexicon,
he ACC/AHA Task Force on Clinical Data Standards has
ndertaken the task to develop and publish clinical data
tandards—data elements and corresponding definitions
hat can be used in the measurement of patient clinical
anagement and outcomes, and for research and epidemi-
logical assessments.
The ACC and AHA recognize the importance of the use
f clinical data for patient management, in the assessment of
atient outcomes, and in research efforts focused on improv-
ng clinical treatment of patients. The goals that the
CC/AHA clinical data standards documents hope to
ulfill by enumeration of key data elements and their
tandardized definitions are as follows:
. Facilitate clinical research by driving standards for infor-
mation gathered in clinical trials.
. Improve cross-comparison of results and clinical out-
comes between different trials and registries.
. Facilitate the development and conduct of future regis-
tries, at both hospital and national levels, by providing a
list of major variables, outcomes, and definitions.
. Become the basis for a standardized medical record
process with the anticipation that medical information
will continue its progress to an electronic format. Data
standards will provide exchange of data across different
electronic medical information systems.
. Enable seamless integration of guidelines through devel-
opment of performance measures and quality assessment
data collection.
II. Methodology for Developing
he Clinical Data Standards
. Selection of Topics for Developing
he Clinical Data Standards
he ACC/AHA Task Force on Clinical Data Standards
elects potential topics for creation of clinical data standards
ased on the importance of the cardiovascular condition
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ACC/AHA Clinical Data Standards February 20, 2007:830–7nd/or procedure that would benefit from the creation of a
et of data standards, as well as the intended purpose (see
he previous listing of goals). The Task Force uses current
CC/AHA Clinical Practice Guidelines and ACC and
HA registries and quality improvement initiatives as a
asis for addressing current and growing areas of interest in
ardiovascular medicine. Once a topic has been selected and
pproved by the Task Force, the next levels of refinement
re carried out by the ACC/AHA Clinical Data Standards
riting Committees. A goal of the Task Force is to publish
he data standards simultaneously with the relevant ACC/
HA guideline or registry initiation.
. Organization and Composition of a
linical Data Standards Writing Committee
. Writing Committee Formation
fter a topic has been selected, the Task Force members
elect the chair of the writing committee, who then works in
onjunction with Task Force members to select the writing
ommittee members.
. Involvement of Related Professional Organizations
hen appropriate, related professional organizations are
nvited to submit nominations to provide expertise in
pecialized areas. From these nominations, the Writing
ommittee Chair, in consultation with the Task Force
hair, selects representatives from each invited professional
rganization to serve on the Writing Committee. These
rganizations will have an opportunity to review the final
ocument and are encouraged to endorse and/or publish it
n their own journals.
. Relationships With Industry
he ACC/AHA Task Force on Clinical Data Standards
akes every effort to avoid any actual or potential conflicts
f interest that may arise as a result of an outside relation-
hip or a personal, professional, or business interest of a
ember of the writing panel. Specifically, all members of
he writing group are required to complete and submit a
isclosure form showing all such relationships that might be
erceived as real or potential conflicts of interest. These
tatements are reviewed by the ACC/AHA Task Force on
linical Data Standards, reported orally to all members
f the writing panel at the first meeting, and updated as
hanges occur. The Writing Committee members’ rela-
ionships with industry are listed in Appendix A. Rela-
ionships with industry for official peer reviewers are
isted in Appendix B.
. Comprehensive Review of Relevant Resources
he ACC/AHA Task Force on Clinical Data Standards
upports gathering candidate data elements and definitions
rom as many relevant resources as possible. Central to the
oundation of all clinical data standards is a comprehensive
eview of published literature and available resources. Ex-
mples of these resources include: oACC/AHA Clinical Practice Guidelines and Other
Relevant National Guidelines: Since current scientific
evidence provides the basis for selection and definition of
data elements, the data elements and definitions should
be linked whenever possible to evidence-based national
guidelines.
Case Report Forms From Previous or Current Clinical
Trials: Existing case report forms and definitions offer a
context that allows Writing Committee members to
visualize how the data elements can be put into practice.
Regional, National, or International Registries: Because
of their experience with various clinical trials and regis-
tries, Writing Committee members can also serve as
valuable resources by sharing relevant data elements and
definitions for review.
National Quality Performance Measurement Initiatives
Existing Clinical Data Standards and Other Sources
Such as the Systematized Nomenclature of Medicine
(SNOMED). Whenever possible, data standards are
congruent across conditions.
. Developing Data Element Sets
he overriding goal in developing clinical data standards
s to focus on important variables needed to assess the
haracteristics of patients, their treatment with both
edication and interventional therapies, and their out-
omes. In developing the standards, the Writing Com-
ittee balances completeness with length and, thus, tries
o be as concise as possible to facilitate use of these
ariables. Standardized definitions for each variable are
rovided. For these, the Writing Committee balances
reater specificity of definitions against what information
an readily and reliably be obtained from a medical record
o make these definitions functional in the various real-
orld settings. Data standards writing committees strive
or clarity, objectivity, and consistency throughout the
riting process.
The Writing Committee pays close attention to the
evel of detail of the information provided about certain
ariables, such as timing of prior cardiovascular events,
iming of procedures, exact drug names versus classes of
rugs, and types of insurance. Users should understand
hat when undertaking a data collection effort, only a
ubset of these elements may be needed or, conversely,
hey may want to consider whether it may be necessary to
ollect elements that have not been included in the data
tandards listing. For instance, if a hospital association
as examining the relationships between patient insur-
nce status, cardiac procedure use, and outcome, the
roup might use more subcategorizations related to
nsurance status. On the other hand, if a pharmaceutical
ompany was conducting a study to evaluate a new drug,
he type of insurance might not matter and could be
mitted. Data elements could also be expanded to include
dditional information, such as an individual listing of all
f the relative contraindications for careful measurement
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February 20, 2007:830–7 ACC/AHA Clinical Data Standardsf quality performance. Expansion of the variables col-
ected would also be expected in the setting of a random-
zed clinical trial of a new drug, for which additional
nformation would be required regarding study proce-
ures, therapies, and outcomes. Technical specifications
elated to the structure of an electronic registry or
atabase, such as field type, parent-child relationship,
nd the like, are not considered part of the data standards
nd will be developed by those who put them to use.
hus, depending on the intended use of the variables, one
ould restrict or expand the number of data elements
sed. In either case, the definitions provided in clinical
ata standards documents should assist in standardizing
he process.
. General Considerations for Developing Clinical Data
tandards
he following list outlines a number of considerations
hich to a greater or lesser degree guide all data standards
riting groups:
. Balance Between Focus and Comprehensiveness. In
developing the data standards for a particular subject
area, the Writing Committee focuses on commonly
collected data elements that are thought to be most
useful for the broadest set of applications. However,
these data standards are not intended to be a compre-
hensive data element catalog encompassing every possi-
ble data need or use. Individual users will likely supple-
ment these elements to suit their individual needs.
Conversely, other users will select only a few data
elements to collect.
. Specific Data Elements Relevant to the Topic. When
possible, the Writing Committee chooses data element
names and definitions common to other ACC/AHA
clinical data standards efforts. However, some elements
are designed to specifically meet the needs of patients
with the specific condition being addressed.
. Varied Clinical Presentations and Care Venues. The
data elements are intended to encompass the full range of
patients with the topic condition or undergoing a topic
procedure/therapy, including acute and chronic presen-
tations and inpatient and outpatient settings, as well as
scheduled and unscheduled medical care encounters.
. Patient-Oriented Format. If the topic condition is chronic
in nature (e.g., heart failure), the individual patient is the
foundation of the data element set. This focus contrasts
with other comparable efforts where the field of interest
may be a procedure (e.g., cardiac catheterization) or an
event (e.g., acute coronary syndrome). Thus, the format of
the data elements will be designed to follow multiple events
over time for each individual patient.
. Date and Time. The Writing Committee recognizes the
critical importance of obtaining dates (and, in some
cases, times) for many data elements in order to under-
stand the clinical course, therapy, and outcomes of the lindividual patient and across populations. The exact date
(month, day, year) for elements, such as health care
encounters, diagnostic and therapeutic procedures, or
changes in therapy, should be obtained whenever possi-
ble. As the ability to obtain precise dates of prior events
may be limited, a best estimate of dates should be
obtained (e.g., month/year), with emphasis placed on the
most current events. The operational format of date
collection will vary depending on particular use.
. Medication Use. Because medical therapies have such an
important effect on the outcomes of patients with a
certain cardiac condition, the data elements and defini-
tions may be relatively detailed in tracking medication use
for those conditions. In some instances, the Writing
Committee may propose that the data on the types of
medications be collected at a minimum of 3 time points:
before the acute event, the first 24 hours after the event,
and at hospital discharge. Furthermore, in cases in which
there may be differences between drugs within a class, it
is suggested that information on the specific medication
within a given medication class be collected.
. Quality of Life. Considerations of quality of life are
particularly important in the management of certain
cardiac conditions. While general health status measures
may be appropriate for some programs and investiga-
tions, more focused, condition-specific measures may be
important to optimize patient care and advance the state
of knowledge for these conditions.
. Risk Adjustment. In some instances, depending on the
topic of the data standards document, the list of data
elements contains factors included in published risk-
adjustment models. Outcomes are adjusted for differ-
ences in patient characteristics and allow better com-
parisons across hospitals, treatment strategies, and
subgroups of patients.
. Resource Utilization. Cost-effectiveness of new and old
therapies and treatment strategies is of growing impor-
tance. The data standards may include items that allow
estimation of resource utilization, which will allow esti-
mation of cardiovascular costs.
. Outcomes. Many outcomes are included in the list of
data elements. These are important for the evaluation of
the clinical benefits and risks of medical and interven-
tional therapies. Some outcome elements may require
review by physicians (e.g., cause of death or the assess-
ment of coronary flow at cardiac catheterization). How-
ever, most outcome elements have simple definitions that
the Writing Committee believes can be abstracted from a
standard medical record.
. Selecting the Data Elements
he standard categories shown in the following outline are
sed when creating the list of data elements. In an effort to
nsure consistency, the published versions of the clinical
ata standards documents all follow a similar format, whichists the key elements and definitions by category.
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I. Demographics
II. Medical History
a. Patient History
i. Cardiovascular
ii. Noncardiovascular
b. Family History
i. Cardiovascular
ii. Noncardiovascular
III. Patient Assessment: Current Signs and
Symptoms
a. Clinical Symptoms
b. Physical Evaluation
IV. Laboratory Testing
V. Presentation to Health Care Facility
a. Admission (Inpatient)
b. Encounter (Outpatient)
VI. Diagnostic Procedures
VII. Invasive Therapeutic Procedures
VIII. Pharmacologic Therapy
a. Cardiac
b. Noncardiac
IX. Patient Education/Counseling
X. Patient Referral
XI. Follow-Up
XII. Outcomes
Based on a review of the applicable resources (described in
ection C), the Writing Committee develops a comprehensive
ist of possible data elements relevant to the chosen topic. This
nitial list is aimed at capturing the universe of potential
lements with the understanding that, by necessity, this set of
ata elements must be limited to those elements most likely to
e needed in data collection efforts for research, clinical care,
nd quality improvement. From this initial list, the Writing
ommittee grades the importance of including each data
lement as “high,” “medium,” or “low.” All of the data elements
ith an average “high” score and the majority of those with an
verage “medium” score are maintained in the set.
The process of writing and revising data element defini-
ions causes many data elements to move into or out of the
et for a variety of reasons. In some instances, an element
hat on its own ranks “low” may be necessary to complete a
ubset of elements pertaining to a related concept. Con-
ersely, an element that ranks “high” may later be deter-
ined to be impossible to define in a manner that facilitates
onsistent data collection, or its content may be contained
ithin another data element.
. Defining Data Elements
he main purpose of each Writing Committee is to
onstruct definitions for topic-specific data elements. Theselements embody the collection of variables specific to the
ardiovascular topic area, the definitions of which come to
epresent the conventional components of these variables.
Once the data element list has been refined to those
eemed to have priority for the first publication of the topic
ata standards, members of the Writing Committee draft
efinitions for those data elements. Sample definitions from
variety of existing sources (see Section C) are provided to
riting Committee members as they draft the definitions
or the specific data standards topic area.
Data definitions are linked whenever possible to the
vidence-based national guidelines, specifically the ACC/
HA clinical practice guidelines. To ensure consistency
cross ACC/AHA clinical data standards, writers are re-
uired to use existing (core) ACC/AHA data standards
efinitions verbatim (e.g., race/ethnic origin, history of
moking) unless there is a compelling reason related to the
pecified topic to change that definition.
The functionality of the definitions is of key importance
hen developing clinical data standards. The general con-
ideration for the level of detail and completeness of data
lement definitions is an evolving process. The definitions
hould be broad enough to be applicable in a variety of data
ollection settings, but specific enough that the data ele-
ents can be uniformly interpreted. Where possible, data
lements are defined in a manner meant to be usable in both
npatient and outpatient settings.
The ACC/AHA recognizes that definitions cannot be
ritten effectively without the context of their intended use. To
acilitate the process of composing definitions, the Writing
ommittee is provided a list of data element types and specific
ses for each. This list is intended to assist Writing Committee
embers in ensuring that the data elements and definitions are
elevant to the purpose of the project. It also represents the
ays in which the data standards can be operationalized and is
egarded as a set of criteria that should be satisfied at this step.
n most circumstances, if a data element does not fulfill at least
of the criteria, its value to users is questioned. Below are 5
ypes of data elements and 4 major environments of data
ollection efforts:
Data Element Types
. Patient Demographics: Provides a description of the patient.
Such information characterizes the patient population.
. Risk Assessment: Allows appropriate identification of
correlates of mortality and other outcomes, which is
required for analysis of risk-adjusted outcomes. It also
allows for clinical risk assessment through identification
of patient characteristics associated with heightened risk
for various adverse outcomes.
. Performance Measurement: Allows measurement of ad-
herence to nationally recognized clinical practice guide-
lines. In some circumstances, some data elements (e.g.,
process of care measures) could be used to construct
performance measures.
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February 20, 2007:830–7 ACC/AHA Clinical Data Standards. Procedural Description: Describes procedures performed
during the episode of care.
. Follow-Up and Outcomes Analysis: Describes elements
used to characterize clinical outcomes and end points
after the care encounter. These may include clinical
outcomes (e.g., mortality, functional status) or economic
outcomes (e.g., resource utilization, length of stay).
Data Collection Environments and Use of Data Standards
Use of data standards depends on the reason clinical data
s collected and the environment for data collection. Exam-
les include:
. Clinical Research/Trials: Strengthen prospective registries
and randomized controlled trials by the use of clinical
data standards. Growing use of data standards will bring
about improved comparison of clinical outcomes be-
tween various trials and registries as well as facilitate data
management.
. Clinical Care: Assist in the organization and design of
electronic medical information initiatives, such as elec-
tronic medical records, pharmacy databases, patient da-
tabases, or other computerized decision support tools.
. Health Services Research: Enhance the systems, delivery,
and outcomes of health services.
. Performance Measurement Initiatives: Facilitate interpre-
tation for non-medical users, such as payers, regulators,
and consumers.
The needs of clinical researchers are frequently unique to the
pecific research objective. This necessitates specific data ele-
ent design and definitions. The definitions proposed in a
elevant data standards document may be considered as a
tarting point. On the other hand, quality performance mea-
urement, particularly when quality comparison is the goal,
equires standard definitions for all data elements. Discussion
f the considerations for use in clinical care and quality
erformance measurement is as much a component of the
onsensus development process as the data definitions them-
elves.
It should be noted that clinical data standards present a
odel of elements which may be employed in data collec-
ion efforts, such as operating a registry, and are not
unctional databases in themselves.
. Consensus Development
he ACC/AHA data standards are consensus, team-
ritten documents that are based on judgments of experts in
he field of cardiology. Writing Committee discussions and
onsensus building are essential to the production of the
linical data standards documents. There are several levels of
efinement that the data elements undergo throughout the
evelopment of the data standards document, necessitating
onstant dialogue and consensus building. Each Writing
ommittee member contributes his or her expertise inonstructing the data elements and corresponding defini- tions. The final document is ultimately a reflection of the
greement of the Writing Committee members on a formal,
ecognized set of clinical data standards.
The Writing Committee meets several times, both in person
nd through conference calls, over the course of the document
evelopment to define and refine the data elements. Through-
ut the creation of the data element set, consensus is developed
hrough discussions (either during face-to-face meetings or
onference calls), e-mails, and occasionally written votes. The
rocess of consensus development allows for the incorporation
f minority opinions in the few instances when a group
onsensus cannot be achieved.
. Peer Review, Public Comment,
nd Board Approval
he following are the review and approval steps taken to
repare the data standards document for publication.
. Peer Review. The set of data elements is independently
reviewed by official reviewers nominated by the ACC
and the AHA, the ACC/AHA Task Force on Clinical
Data Standards, and independent content reviewers.
. 30-Day Public Comment. To increase its applicability
further, the document is posted on the ACC Web site
(www.acc.org) for a 30-day public comment period.
. Resolution of Comments Received. After the peer
review and the 30-day public comments are received, the
Writing Committee Chair is responsible for comment
resolution and finalization of the document, with input
as requested from members of the Writing Committee.
. Final Writing Committee Approval. After the Chair
has completed the resolution of the comments in the
document, the Writing Committee reviews the docu-
ment and indicates their final approval.
. ACC and AHA Governing Body Approval. The doc-
ument must be approved for publication by the govern-
ing bodies of the ACC and the AHA.
. Endorsement. At this point, the document is sent to
relevant professional associations for consideration of
formal endorsement.
The document will be considered current until review by the
CC/AHA Task Force on Clinical Data Standards deter-
ines that a revision is necessary (see the following section).
. Publication and Promotion of
linical Data Standards
he introduction, data element, and definition sections of the
linical data standards document are published in the Journal of
merican College of Cardiology and Circulation. Revised clinical
ata standards will be published on the Web.
. Updates and Revisions
imilar to guidelines and performance measures, data stan-
ards require regular review and updating. The Writing
ommittee Chair, in conjunction with the Writing Commit-ee members, will review the clinical data standards document
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he document needs to be updated. Updates may be reflective
f changes in relevant medical literature, including revised
CC/AHA practice guidelines, advances in cardiovascular
edicine, or changes in the feasibility of collecting data
lements in practice.
V. Conclusions
he ACC/AHA Task Force on Clinical Data Standards looks
orward to the increasing use of the data standards documents
nd the data element definitions. The Task Force welcomes
nput from members and users. It is through their use, revision,
nd updating that clinical data standards find their place in the
ervice and resource they offer to our ACC and AHA members
nd other constituencies. Ataff
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